Market capitalization | $345.62m |
Enterprise Value | $132.24m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 1.27 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-62.30m |
Cash position | $238.40m |
EPS (TTM) EPS | $-1.50 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.
10 Analysts have issued a EnGene forecast:
10 Analysts have issued a EnGene forecast:
Oct '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.32 -0.32 |
78%
78%
|
|
EBITDA | -62 -62 |
88%
88%
|
EBIT (Operating Income) EBIT | -62 -62 |
88%
88%
|
Net Profit | -55 -55 |
46%
46%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
Head office | Canada |
CEO | Ronald Cooper |
Employees | 57 |
Founded | 2023 |
Website | www.engene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.